Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FULC 
Fulcrum Therapeutics Inc (FULC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: FULC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -71.72% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 162.48M USD | Price to earnings Ratio - | 1Y Target Price 5.67 |
Price to earnings Ratio - | 1Y Target Price 5.67 | ||
Volume (30-day avg) 432486 | Beta 2.19 | 52 Weeks Range 2.67 - 10.13 | Updated Date 03/31/2025 |
52 Weeks Range 2.67 - 10.13 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -12.16% | Operating Margin (TTM) -24.79% |
Management Effectiveness
Return on Assets (TTM) -4.78% | Return on Equity (TTM) -4.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -76931599 | Price to Sales(TTM) 2.03 |
Enterprise Value -76931599 | Price to Sales(TTM) 2.03 | ||
Enterprise Value to Revenue 117.4 | Enterprise Value to EBITDA -3.09 | Shares Outstanding 53979300 | Shares Floating 26503299 |
Shares Outstanding 53979300 | Shares Floating 26503299 | ||
Percent Insiders 1.87 | Percent Institutions 97.17 |
Analyst Ratings
Rating 3.29 | Target Price 5.67 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 4 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Fulcrum Therapeutics Inc
Company Overview
History and Background
Fulcrum Therapeutics Inc. was founded in 2016. It is a biopharmaceutical company focused on developing therapies for genetically defined diseases. Key milestones include clinical trials for losmapimod in facioscapulohumeral muscular dystrophy (FSHD) and for other rare genetic diseases.
Core Business Areas
- Drug Development: Focuses on discovering and developing small molecule therapies to target disease-modifying mechanisms in genetically defined diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team includes Robert J. Gould, Ph.D. (President and CEO). The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- Losmapimod: Losmapimod is Fulcrum's lead product candidate for the treatment of FSHD. Competitors include companies developing gene therapies and other small molecule approaches for FSHD. There is no established, effective treatment for FSHD, so losmapimod aims to capture a significant market share if approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and heavily regulated, with significant investment in research and development.
Positioning
Fulcrum is positioned as a company specializing in genetically defined diseases, leveraging its expertise to develop targeted therapies. Its competitive advantage lies in its focus on validated biological targets and its proprietary product engine.
Total Addressable Market (TAM)
The TAM for FSHD is estimated to be substantial, given the lack of effective treatments and the prevalence of the disease. Fulcrum aims to capture a significant portion of this market with losmapimod. Precise TAM values vary depending on pricing assumptions and market penetration rates but can easily exceed $1 billion.
Upturn SWOT Analysis
Strengths
- Focus on genetically defined diseases
- Proprietary product engine
- Experienced management team
Weaknesses
- Dependence on single lead product candidate (Losmapimod)
- Limited commercial infrastructure
- High cash burn rate
Opportunities
- Expansion into additional genetically defined diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results for Losmapimod
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing therapies for similar diseases
Competitors and Market Share
Key Competitors
- Vertex Pharmaceuticals (VRTX)
- Biogen (BIIB)
- Avidity Biosciences, Inc (RNA)
Competitive Landscape
Fulcrum faces competition from larger pharmaceutical companies with more resources and established commercial infrastructure. Its competitive advantage lies in its specialized focus and proprietary technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expanding R&D efforts and increasing clinical trial activity.
Future Projections: Future growth depends on the successful development and commercialization of Losmapimod and other pipeline candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing Losmapimod through clinical trials and expanding the pipeline with new drug candidates.
Summary
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on genetically defined diseases and it has potential with its lead product candidate. The company faces significant risks associated with clinical trials and regulatory approvals. It relies heavily on the success of Losmapimod, presenting a concentration risk. Successful results and partnerships are needed to succeed.
Similar Companies
- VRTX
- BIIB
- RNA
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fulcrum Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2019-07-18 | CEO, President & Director Mr. Alexander C. Sapir | ||
Sector Healthcare | Industry Biotechnology | Full time employees 45 | Website https://www.fulcrumtx.com |
Full time employees 45 | Website https://www.fulcrumtx.com | ||
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.